Modelling Adverse Events in Patients Receiving Chronic Oral Corticosteroids in the UK

Danny Gibson (), Neil Branscombe, Neil Martin, Andrew Menzies-Gow, Priya Jain, Katherine Padgett and Florian Yeates
Additional contact information
Danny Gibson: AstraZeneca, Health Economics
Neil Branscombe: AstraZeneca, Health Economics
Neil Martin: AstraZeneca, Health Economics
Andrew Menzies-Gow: AstraZeneca, Health Economics
Priya Jain: AstraZeneca, Health Economics
Katherine Padgett: Health Economics and Outcomes Research Ltd
Florian Yeates: Health Economics and Outcomes Research Ltd

PharmacoEconomics - Open, 2024, vol. 8, issue 6, No 12, 923-934

Abstract: Abstract Background Oral corticosteroids (OCS) are effective anti-inflammatory agents used across a range of conditions. However, substantial evidence associates their use with increased risks for adverse events (AEs), causing high burden on healthcare resources. Emerging biologics present as alternative agents, enabling the reduction of OCS use. However, current modelling approaches may underestimate their effects by not capturing OCS-sparing effects. In this study, we present a modelling approach designed to capture the health economic benefits of OCS-sparing regimens and agents. Methods We developed a disease-agnostic model using a UK health technology assessment (HTA) perspective, with discounting of 3.5% for costs and outcomes, a lifetime horizon, and 4-week cycle length. The model structure included type 2 diabetes mellitus, established cardiovascular disease, and osteoporosis as key AEs and drivers of morbidity and mortality, as well as capturing transient events. Quality-adjusted life-years (QALYs), life-years, and costs were determined for OCS-only and OCS-sparing treatment arms. Outcomes were determined using baseline 50% OCS-sparing, considering several OCS average daily doses (5, 10, 15 mg). Results A treatment regimen with 50% OCS dose-sparing led to lifetime incremental cost savings per patient of £1107 (95% confidence interval £1014–£1229) at 5 mg, £2403 (£2203–£2668) at 10 mg, and £19,501 (£748–£51,836) at 15 mg. Patients also gained 0.033 (0.030–0.036) to 0.356 (0.022–2.404) QALYs dependent on dose. The benefits of OCS sparing were long-term, plateauing after 35–40 years of treatment. Conclusions We present a modelling approach that captures additional long-term health economic benefits from OCS sparing that would otherwise be missed from current modelling approaches. These results may help inform future decision making for emerging OCS-sparing therapeutics by comparing them against the cost of such treatments.

Date: 2024
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
http://link.springer.com/10.1007/s41669-024-00520-8 Abstract (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:spr:pharmo:v:8:y:2024:i:6:d:10.1007_s41669-024-00520-8

Ordering information: This journal article can be ordered from
http://www.springer.com/adis/journal/41669

DOI: 10.1007/s41669-024-00520-8

Access Statistics for this article

PharmacoEconomics - Open is currently edited by Timothy Wrightson and Christopher Carswell

More articles in PharmacoEconomics - Open from Springer
Bibliographic data for series maintained by Sonal Shukla () and Springer Nature Abstracting and Indexing ().